bioAffinity Technologies
BIAFW
4 hedge funds and large institutions have $343K invested in bioAffinity Technologies in 2024 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 1 closing their positions.
240% more capital invested
Capital invested by funds: $101K → $343K (+$242K)
0% more funds holding
Funds holding: 4 → 4 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
0.14% less ownership
Funds ownership: 2.73% → 2.6% (-0.14%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$17.6K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$485 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Clear Street
New York
|
-$11.5K |
| 2 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
-$5.94K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AC
1
Armistice Capital
New York
| $235K | – | – | – |
|
|
CS
2
Clear Street
New York
| $63.2K | -$11.5K | -11,083 | -17% |
|
|
3
Citadel Advisors
Miami,
Florida
| $45.1K | +$17.6K | +16,959 | +76% |
|
|
4
UBS Group
Zurich,
Switzerland
| $537 | +$485 | +467 | New |
|
|
WAM
5
Warberg Asset Management
Winnetka,
Illinois
| – | -$5.94K | -14,476 | Closed |
|
BIAFW Hedge Fund Activity: Q3 2024 in Review
4 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in bioAffinity Technologies (BIAFW) for Q3 2024, worth a combined $343K — up 240% from $101K a quarter earlier.
Fund positioning in BIAFW was balanced in Q3 2024: 1 fund opened new positions, 1 closed out, 1 added to existing stakes and 1 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $17.6K. The largest seller was Clear Street, cutting an estimated $11.5K.
- 4 institutional investors held bioAffinity Technologies (BIAFW) as of Q3 2024, unchanged from Q2 2024.
- Funds reported $343K of bioAffinity Technologies stock for Q3 2024, up 240% quarter-over-quarter.
- 1 fund opened new bioAffinity Technologies positions in Q3 2024 and 1 closed out, a net change of 0 holders.
- The largest bioAffinity Technologies buyer in Q3 2024 was Citadel Advisors, an estimated $17.6K added.
- The largest bioAffinity Technologies seller in Q3 2024 was Clear Street, an estimated $11.5K sold.
Based on aggregated 13F filings for Q3 2024.